Refine
Document Type
- Article (46)
- Doctoral Thesis (1)
Language
- English (47)
Has Fulltext
- yes (47)
Is part of the Bibliography
- no (47)
Keywords
- - (37)
- plasma medicine (25)
- reactive oxygen species (16)
- ROS (14)
- cold physical plasma (11)
- kINPen (8)
- reactive oxygen and nitrogen species (7)
- cold atmospheric pressure plasma (5)
- oncology (5)
- CAP (4)
- RNS (4)
- cytokines (4)
- apoptosis (3)
- chemokines (3)
- cold atmospheric plasma (3)
- CRISPR/Cas9 genome editing (2)
- HL-60 (2)
- THP-1 (2)
- anticancer drugs (2)
- cancer (2)
- cancer therapy (2)
- cerebral cavernous malformation (2)
- combination therapy (2)
- mesenchymal stromal cells (2)
- metastasis (2)
- osteosarcoma (2)
- skin cancer (2)
- Antimicrobial (1)
- Apoptosis (1)
- Atmospheric pressure plasma (1)
- BRAF (1)
- Biofilm (1)
- CAL 78 (1)
- CAM (1)
- CCL17 (1)
- CCL22 (1)
- CCM1 (1)
- CCM1/KRIT1 (1)
- CRISPR/Cas9 (1)
- Cancer (1)
- Cerebral cavernous malformations (1)
- Co-culture (1)
- Cold physical plasma (1)
- Dielectric barrier discharge (1)
- Ewing’s sarcoma (1)
- HNSCC (1)
- Hsp27 (1)
- Kaltes Plasma (1)
- LNCaP (1)
- Leukozyten (1)
- M2 macrophages (1)
- MNT-1 (1)
- MidiPLexc (1)
- NSC59984 (1)
- Oncology (1)
- PC3 (1)
- PDA6606 (1)
- PEF (1)
- PTW (1)
- Plasmamedizin (1)
- RNA sequencing (1)
- RNA-Seq (1)
- Reactive oxygen and nitrogen species (1)
- SK-MEL-28 (1)
- SKH1 mouse model (1)
- SW 1353 (1)
- Surface barrier discharge plasma source (1)
- T-cells (1)
- TAMs (1)
- TUNEL assay (1)
- Tumor-like behavior (1)
- Urology (1)
- Wound management (1)
- Wundheilung (1)
- allografts (1)
- antimicrobial (1)
- antimicrobial therapy (1)
- arthroplasty (1)
- atmospheric pressure argon plasma jet (1)
- biofilm degradation (1)
- blood outgrowth endothelial cells (1)
- brain tumor (1)
- cancellous bone (1)
- cancer immunity (1)
- caspase-3/7 assay (1)
- cell migration (1)
- chaperones (1)
- chondrosarcoma (1)
- chronic wounds (1)
- cluster formation (1)
- cold argon plasma (1)
- cold plasma (1)
- colorectal cancer (1)
- damage-associated molecular patterns (1)
- decontamination (1)
- dermal full-thickness wounds (1)
- dermatology (1)
- endothelial cells VEGF (1)
- endothelial-specific gene expression (1)
- epithelial-to-mesenchymal transition (1)
- food production industry (1)
- food spoilage (1)
- gas plasma technology (1)
- growth inhibition (1)
- growth inhibitory effect (1)
- head and neck squamous cell carcinoma (1)
- heat-shock proteins (1)
- hemostasis (1)
- hydrogen peroxide (1)
- hypochlorous acid (1)
- iPSC-derived endothelial cells (1)
- iPSCs (1)
- immunogenicity (1)
- immunomodulation (1)
- inactivation (1)
- infected wounds (1)
- inflammation (1)
- kINPen MED (1)
- kINPen plasma jet (1)
- keratinocytes (1)
- leucocytes (1)
- live/dead cell imaging (1)
- macrophages (1)
- mass spectrometry (1)
- matrix metalloproteinase (1)
- medical gas plasma technology (1)
- membrane functionality (1)
- membrane integrity (1)
- migration (1)
- moDCs (1)
- monocytes (1)
- mucosal diseases (1)
- osteogenic differentiation (1)
- pancreatic cancer (1)
- patient-derived xenografts (1)
- peptidases (1)
- peroxynitrite (1)
- plasma discharge (1)
- plasma oncology (1)
- plasma sources (1)
- post-translational modifications (1)
- radius cell migration assay (1)
- reactive nitrogen species (1)
- redox regulation (1)
- resin (1)
- risk evaluation (1)
- screening (1)
- skeletal regeneration (1)
- surface modification (1)
- sustainability (1)
- synchrotron radiation computed tomography (1)
- tumor immunology (1)
- tumor microenvironment (TME) (1)
- tumor spheroids (1)
- tumor-associated macrophages (1)
- viability (1)
- von Willebrand factor (1)
- wound healing (1)
Institute
- Klinik und Poliklinik für Chirurgie Abt. für Viszeral-, Thorax- und Gefäßchirurgie (11)
- Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie/Plastische Operationen (10)
- Klinik und Poliklinik für Chirurgie Abt. für Unfall- und Wiederherstellungschirurgie (7)
- Institut für Hygiene und Umweltmedizin (5)
- Klinik und Poliklinik für Orthopädie und Orthopädische Chirurgie (3)
- Klinik und Poliklinik für Urologie (3)
- Abteilung für Mikrobiologie und Molekularbiologie (2)
- Institut für Humangenetik (2)
- Institut für Immunologie u. Transfusionsmedizin - Abteilung Immunologie (1)
- Institut für Mikrobiologie - Abteilung für Genetik & Biochemie (1)
- Institut für Pharmakologie (1)
- Institut für Physik (1)
- Interfakultäres Institut für Genetik und Funktionelle Genomforschung (UMG) (1)
- Klinik für Herz-, Thorax- und Gefäßchirurgie - Klinikum Karlsburg (1)
- Klinik und Poliklinik für Neurochirurgie (1)
Publisher
The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and the excellence research program ONKOTHER-H (Rostock/Greifswald, Germany). The meeting showcased cutting-edge research and liberated discussions on the application of therapeutic ROS and immunology in cancer treatment, primarily focusing on gas plasma technology. The 2-day hybrid meeting took place in Greifswald and online from 15–16 July 2021, facilitating a wide range of participants totaling 66 scientists from 12 countries and 5 continents. The meeting aimed at bringing together researchers from a variety of disciplines, including chemists, biochemists, biologists, engineers, immunologists, physicists, and physicians for interdisciplinary discussions on using therapeutic ROS and medical gas plasma technology in cancer therapy with the four main sessions: “Plasma, Cancer, Immunity”, “Plasma combination therapies”, “Plasma risk assessment and patients studies”, and “Plasma mechanisms and treated liquids in cancer”. This conference report outlines the abstracts of attending scientists submitted to this meeting.
The requirements for new technologies to serve as anticancer agents go far beyond their toxicity potential. Novel applications also need to be safe on a molecular and patient level. In a broader sense, this also relates to cancer metastasis and inflammation. In a previous study, the toxicity of an atmospheric pressure argon plasma jet in four human pancreatic cancer cell lines was confirmed and plasma treatment did not promote metastasis in vitro and in ovo. Here, these results are extended by additional types of analysis and new models to validate and define on a molecular level the changes related to metastatic processes in pancreatic cancer cells following plasma treatment in vitro and in ovo. In solid tumors that were grown on the chorion-allantois membrane of fertilized chicken eggs (TUM-CAM), plasma treatment induced modest to profound apoptosis in the tissues. This, however, was not associated with a change in the expression levels of adhesion molecules, as shown using immunofluorescence of ultrathin tissue sections. Culturing of the cells detached from these solid tumors for 6d revealed a similar or smaller total growth area and expression of ZEB1, a transcription factor associated with cancer metastasis, in the plasma-treated pancreatic cancer tissues. Analysis of in vitro and in ovo supernatants of 13 different cytokines and chemokines revealed cell line-specific effects of the plasma treatment but a noticeable increase of, e.g., growth-promoting interleukin 10 was not observed. Moreover, markers of epithelial-to-mesenchymal transition (EMT), a metastasis-promoting cellular program, were investigated. Plasma-treated pancreatic cancer cells did not present an EMT-profile. Finally, a realistic 3D tumor spheroid co-culture model with pancreatic stellate cells was employed, and the invasive properties in a gel-like cellular matrix were investigated. Tumor outgrowth and spread was similar or decreased in the plasma conditions. Altogether, these results provide valuable insights into the effect of plasma treatment on metastasis-related properties of cancer cells and did not suggest EMT-promoting effects of this novel cancer therapy.
Background: Plasma-generated compounds (PGCs) such as plasma-processed air (PPA) or plasma-treated water (PTW) offer an increasingly important alternative for the control of microorganisms in hard-to-reach areas found in several industrial applications including the food industry. To this end, we studied the antimicrobial capacity of PTW on the vitality and biofilm formation of Listeria monocytogenes, a common foodborne pathogen.
Results: Using a microwave plasma (MidiPLexc), 10 ml of deionized water was treated for 100, 300, and 900 s (pre-treatment time), after which the bacterial biofilm was exposed to the PTW for 1, 3, and 5 min (post-treatment time) for each pre-treatment time, separately. Colony-forming units (CFU) were significantly reduced by 4.7 log10 ± 0.29 log10, as well as the metabolic activity decreased by 47.9 ± 9.47% and the cell vitality by 69.5 ± 2.1%, compared to the control biofilms. LIVE/DEAD staining and fluorescence microscopy showed a positive correlation between treatment and incubation times, as well as reduction in vitality. Atomic force microscopy (AFM) indicated changes in the structure quality of the bacterial biofilm.
Conclusion: These results indicate a promising antimicrobial impact of plasma-treated water on Listeria monocytogenes, which may lead to more targeted applications of plasma decontamination in the food industry in the future.
Reactive oxygen species (ROS) have been subject of increasing interest in the pathophysiology and therapy of cancers in recent years. In skin cancer, ROS are involved in UV-induced tumorigenesis and its targeted treatment via, e.g., photodynamic therapy. Another recent technology for topical ROS generation is cold physical plasma, a partially ionized gas expelling dozens of reactive species onto its treatment target. Gas plasma technology is accredited for its wound-healing abilities in Europe, and current clinical evidence suggests that it may have beneficial effects against actinic keratosis. Since the concept of hormesis dictates that low ROS levels perform signaling functions, while high ROS levels cause damage, we investigated herein the antitumor activity of gas plasma in non-melanoma skin cancer. In vitro, gas plasma exposure diminished the metabolic activity, preferentially in squamous cell carcinoma cell (SCC) lines compared to non-malignant HaCaT cells. In patient-derived basal cell carcinoma (BCC) and SCC samples treated with gas plasma ex vivo, increased apoptosis was found in both cancer types. Moreover, the immunomodulatory actions of gas plasma treatment were found affecting, e.g., the expression of CD86 and the number of regulatory T-cells. The supernatants of these ex vivo cultured tumors were quantitatively screened for cytokines, chemokines, and growth factors, identifying CCL5 and GM-CSF, molecules associated with skin cancer metastasis, to be markedly decreased. These findings suggest gas plasma treatment to be an interesting future technology for non-melanoma skin cancer topical therapy.
Cold physical plasma (CPP) technology is of high promise for various medical applications.
The interplay of specific components of physical plasma with living cells, tissues and organs on a structural and functional level is of paramount interest with the aim to induce therapeutic effects in a controlled and replicable fashion.
In contrast to other medical disciplines such as dermatology and oromaxillofacial surgery, research reports on CPP application in orthopaedics are scarce.
The present implementation of CPP in orthopaedics involves surface modifications of orthopaedic materials and biomaterials to optimize osseointegration. In addition, the influence of CPP on musculoskeletal cells and tissues is a focus of research, including possible adverse reactions and side effects. Its bactericidal aspects make CPP an attractive supplement to current treatment regimens in case of microbial inflammations such as periprosthetic joint infections. Attributed anticancerogenic and pro-apoptotic effects underline the clinical relevance of CPP as an additive in treating malignant bone lesions.
The present review outlines ongoing research in orthopaedics involving CPP; it distinguishes considerations for safe application and the need for more evidence-based research to facilitate robust clinical implementation.
Multiple evidence in animal models and in humans suggest a beneficial role of cold physical
plasma in wound treatment. Yet, risk assessment studies are important to further foster therapeutic
advancement and acceptance of cold plasma in clinics. Accordingly, we investigated the long-term
side effects of repetitive plasma treatment over 14 consecutive days in a rodent full-thickness ear
wound model. Subsequently, animals were housed for 350 days and sacrificed thereafter. In blood,
systemic changes of the pro-inflammatory cytokines interleukin 1β and tumor necrosis factor α
were absent. Similarly, tumor marker levels of α-fetoprotein and calcitonin remained unchanged.
Using quantitative PCR, the expression levels of several cytokines and tumor markers in liver,
lung, and skin were found to be similar in the control and treatment group as well. Likewise,
histological and immunohistochemical analysis failed to detect abnormal morphological changes
and the presence of tumor markers such as carcinoembryonic antigen, α-fetoprotein, or the neighbor
of Punc 11. Absence of neoplastic lesions was confirmed by non-invasive imaging methods such as
anatomical magnetic resonance imaging and positron emission tomography-computed tomography.
Our results suggest that the beneficial effects of cold plasma in wound healing come without apparent
side effects including tumor formation or chronic inflammation.
(1) Background: Chondrosarcoma (CS) is a malignant primary bone tumor with a cartilaginous origin. Its slow cell division and severely restricted vascularization are responsible for its poor responsiveness to chemotherapy and radiotherapy. The decisive factor for the prognosis of CS patients is the only adequate therapy—surgical resection. Cold atmospheric pressure plasma (CAP) is emerging as a new option in anti-cancer therapy. Its effect on chondrosarcomas has been poorly investigated. (2) Methods: Two CS cell lines—SW 1353 and CAL 78—were used. Various assays, such as cell growth kinetics, glucose uptake, and metabolic activity assay, along with two different apoptosis assays were performed after CAP treatment. A radius cell migration assay was used to examine cell motility. (3) Results: Both cell lines showed different growth behavior, which was taken into account when using the assays. After CAP treatment, a reduction in metabolic activity was observed in both cell lines. The immediate effect of CAP showed a reduction in cell numbers and in influence on this cell line’s growth rate. The measurement of the glucose concentration in the cell culture medium showed an increase after CAP treatment. Live-dead cell imaging shows an increase in the proportion of dead cells over the incubation time for both cell lines. There was a significant increase in apoptotic signals after 48 h and 72 h for both cell lines in both assays. The migration assay showed that CAP treatment inhibited the motility of chondrosarcoma cells. The effects in all experiments were related to the duration of CAP exposure. (4) Conclusions: The CAP treatment of CS cells inhibits their growth, motility, and metabolism by initiating apoptotic processes.